Studying Health Outcomes After Treatment in Patients With Retinoblastoma | MicrobiomeTrials

← Back to trials

NCT03932786

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

RecruitingOBSERVATIONAL

Trial Details

Start: 2019-01-24Est. Completion: 2030-01

Enrollment target: 900 participants

Locations

Lurie Children's Hospital, Chicago, Illinois, United States
University of Illinois, Chicago, Chicago, Illinois, United States
University of Minnesoa, Minneapolis, Minnesota, United States
Washington School of Medicine at St. Louis, St Louis, Missouri, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Texas Childeren's Hospital, Houston, Texas, United States
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
The Hosptial for Sick Children, Toronto, Canada

Contact

Vanderbilt-Ingram Service for Timely Access

Other microbiome trials you might be interested in

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasPhase 1Recruiting

Neurofibromatosis 1

Background: NF1 is a genetic disease that causes tumors called atypical neurofibromas. These tumors, which arise from n…

Bethesda, United StatesEst. completion Dec 31, 2028

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)Phase 2Completed

NSCLCMetastatic Colorectal CarcinomaRefractory Melanoma

The primary goal of this trial is to assess clinical response to nivolumab and pixatimod, and, nivolumab, pixatimod and …

Pittsburgh, United StatesCompleted Feb 5, 2024

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.